利索-全球专利检索

  1. 登录
  2. 注册
发明公开
CN102526705A 人类核糖体蛋白L23标签多肽在制备抗癌药物中的应用 有权

人类核糖体蛋白L23标签多肽在制备抗癌药物中的应用
摘要：
本发明公开了人类核糖体蛋白L23标签多肽在制备抗癌药物中的应用，所述人类核糖体蛋白L23标签多肽的氨基酸序列由SEQ ID NO：1定义。人类核糖体蛋白L23标签多肽对人乳腺癌Bcap-37的生长抑制率具有时间和剂量的依赖性。在0.2，0.5和0.8μg/ml浓度下对人乳腺癌Bcap-37生长抑制有较好的效果，其中浓度0.5μg/ml时人类核糖体蛋白L23标签多肽对人乳腺癌Bcap-37细胞的生长抑制率最好，达到72.29％。
摘要（英）：

The invention discloses application of human ribosomal protein L23 label peptide to preparation of anti-cancer medicines. The amino acid sequence of the human ribosomal protein L23 label peptide is defined by SEQ ID NO:1. The human ribosomal protein L23 label peptide has time and dose dependence on growth inhibition rate of human breast cancer Bcap-37. The human ribosomal protein L23 label peptide at the concentrations of 0.2, 0.5 and 0.8 ug/ml has a good effect on growth inhibition of the human breast cancer Bcap-37, wherein the growth inhibition ratio of the human ribosomal protein L23 label peptide at the concentration of 0.5 ug/ml on the human breast cancer Bcap-37 is highest and reaches 72.29 percent.

公开/授权文献
0/0